199 related articles for article (PubMed ID: 17598983)
1. Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways.
Song H; Xu Y
Cell Cycle; 2007 Jul; 6(13):1570-3. PubMed ID: 17598983
[TBL] [Abstract][Full Text] [Related]
2. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
3. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
4. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
5. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis.
Lu X; Liu DP; Xu Y
Oncogene; 2013 Jun; 32(23):2900-6. PubMed ID: 22824795
[TBL] [Abstract][Full Text] [Related]
6. Promyelocytic leukemia protein is required for gain of function by mutant p53.
Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
8. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
11. Functional interaction of H2AX, NBS1, and p53 in ATM-dependent DNA damage responses and tumor suppression.
Kang J; Ferguson D; Song H; Bassing C; Eckersdorff M; Alt FW; Xu Y
Mol Cell Biol; 2005 Jan; 25(2):661-70. PubMed ID: 15632067
[TBL] [Abstract][Full Text] [Related]
12. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models.
Kenzelmann Broz D; Attardi LD
Carcinogenesis; 2010 Aug; 31(8):1311-8. PubMed ID: 20097732
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
14. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 proteins: between loss and gain of function.
Strano S; Dell'Orso S; Mongiovi AM; Monti O; Lapi E; Di Agostino S; Fontemaggi G; Blandino G
Head Neck; 2007 May; 29(5):488-96. PubMed ID: 17123310
[TBL] [Abstract][Full Text] [Related]
17. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
Dearth LR; Qian H; Wang T; Baroni TE; Zeng J; Chen SW; Yi SY; Brachmann RK
Carcinogenesis; 2007 Feb; 28(2):289-98. PubMed ID: 16861262
[TBL] [Abstract][Full Text] [Related]
18. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
Monteith JA; Mellert H; Sammons MA; Kuswanto LA; Sykes SM; Resnick-Silverman L; Manfredi JJ; Berger SL; McMahon SB
Mol Oncol; 2016 Oct; 10(8):1207-20. PubMed ID: 27341992
[TBL] [Abstract][Full Text] [Related]
19. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic roles of p53 mutants in mouse models.
Lozano G
Curr Opin Genet Dev; 2007 Feb; 17(1):66-70. PubMed ID: 17208429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]